Concord Drugs Ltd

Concord Drugs, a microcap in the Pharmaceuticals & Drugs sector, faced significant volatility, hitting a new 52-week low. The stock has underperformed its sector and consistently traded below key moving averages. Over the past year, it has declined notably, contrasting with the overall market's gains.

Concord Drugs, a microcap in the Pharmaceuticals & Drugs sector, faced significant volatility, hitting a new 52-week low. The stock has underperformed its sector and consistently traded below key moving averages. Over the past year, it has declined notably, contrasting with the overall market's gains.

Concord Drugs, a microcap in the Pharmaceuticals & Drugs sector, faced significant volatility, hitting a new 52-week low. The stock has underperformed its sector and consistently traded below key moving averages. Over the past year, it has declined notably, contrasting with the overall market's gains.

Concord Drugs has released its financial results for Q3 of fiscal year 2024-25, highlighting significant improvements in operating profit and profit margins, alongside increased earnings per share. However, the company faced challenges with net sales, which declined year-on-year, marking the lowest level in five quarters.

Concord Drugs has recently undergone a revision in its score by MarketsMOJO, reflecting concerns over its financial health. The company has shown a decline in key performance metrics, including net sales growth and profitability. Additionally, promoter confidence has decreased, with a reduction in holdings. Despite a recent uptick in quarterly sales, the stock continues to lag behind the market.

Concord Drugs has recently seen a revision in its stock evaluation by MarketsMOJO, reflecting a shift in market sentiment. The company reported strong financial results with significant sales growth, although long-term fundamentals remain a concern. Additionally, the stock has been added to MarketsMOJO's list, indicating renewed interest.

Concord Drugs has recently experienced a revision in its score from MarketsMOJO, reflecting concerns over its long-term fundamental strength. Despite a notable increase in net sales last quarter, the company's overall performance indicators, including profitability and market returns, suggest a challenging outlook for investors.

Concord Drugs has recently experienced a revision in its score from MarketsMOJO, reflecting changes in its market position and performance indicators. Despite a notable increase in net sales, the company faces challenges with long-term growth and profitability. Additionally, a decline in promoter confidence raises concerns about its future prospects.

Despite receiving a 'Sell' call from MarketsMOJO, Concord Drugs has shown a significant growth in net sales and overall financial performance in the second quarter of fiscal year 2024-2025. This is a result of the company's strong sales trend and focus on providing quality products and services in the pharmaceutical industry.

Concord Drugs, a microcap pharmaceutical company, reported a decline in net sales and operating profit for the quarter ending June 2024. The company's net sales were at Rs 6.35 crore, a decrease of 27.76% compared to the same quarter last year. This has resulted in a negative trend in the near term, with the lowest operating profit in the last five quarters. MarketsMOJO has given a 'Strong Sell' call for the company's stock, and investors should consider the company's financial performance before making any investment decisions.

Concord Drugs, a microcap pharmaceutical company, has reported a flat performance in the quarter ending March 2024, with a score of -2. However, net sales have increased by 27.05% from the same quarter last year, while operating profit and PBT have decreased. MarketsMOJO has given a 'Sell' call for the stock.

Concord Drugs, a microcap pharmaceutical company, has reported a negative performance in the quarter ending December 2023. The company's net sales, operating profit, operating profit margin, profit before tax, and earnings per share have all seen a decline, leading to a 'Sell' call by MarketsMOJO. Investors and experts are advised to closely monitor the company's future performance.

Concord Drugs, a microcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to weak long-term fundamental strength and poor debt servicing ability. However, the stock has some bullish factors, including a ROCE of 7.6 and attractive valuation. The company has a track record of market-beating performance, but investors should carefully evaluate its current financial health before investing.

Concord Drugs, a microcap pharmaceutical company, has received an upgraded stock call from MarketsMOJO to a 'Hold' rating. The stock's technical trend has improved to Bullish, with a Very Attractive ROCE and low Enterprise value to Capital Employed ratio. However, the company's long-term fundamentals and debt-servicing ability may be a cause for caution.

Concord Drugs, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to weak long-term fundamentals. The company has shown poor net sales growth, weak ability to service debt, and low profitability per unit of shareholders' funds. While there are some positive technical factors, investors should carefully consider the company's struggling financials before making any investment decisions.

Concord Drugs, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its attractive valuation and recent bullish trend. However, its long-term fundamentals are weak with low sales growth and profitability, and investors should carefully consider these factors before making any investment decisions.

Concord Drugs, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to weak long-term fundamentals and concerns about debt servicing. Despite a recent flat quarter, the stock is technically bullish and has an attractive valuation. However, with a PEG ratio of 0.5 and a recent downgrade, investors may want to approach with caution.

Concord Drugs, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO on December 5, 2023. The stock is currently in a Mildly Bullish range and has shown bullish indicators such as MACD, Bollinger Band, and KST. However, the company's long-term fundamentals are weak with low net sales growth and profitability, raising concerns for potential investors.

Concord Drugs, a microcap pharmaceutical company, has reported a decrease in net sales by 16.04% for the quarter ended September 2023. However, its standalone net profit and operating profit have shown positive growth. The company's stock call is 'Hold' according to MarketsMOJO, with some positive indicators but also areas for improvement.